Multiple Sclerosis (MS)

Around one million people in the US live with Multiple Sclerosis (MS), yet many eligible patients are not escalated to high-efficacy therapy in time.
About Multiple Sclerosis
In numbers
  • Around one million people live with MS in the United States, at a prevalence of roughly 300 per 100,000, making it the most common non-traumatic disabling neurological condition in young adults.
  • Global prevalence is estimated at 2.22 million.
  • Women are affected nearly three times as often as men, at a ratio of approximately 2.8 to 1.
  Special details
  • Prevalence rises with distance from the equator, reaching around 400 per 100,000 in the northern United States and Canada.
  • Rates also vary by ethnicity, at roughly 375 per 100,000 among non-Hispanic white populations compared with about 161 per 100,000 among Hispanic populations.
  • An estimated 500,000 to 600,000 US patients are on a disease-modifying therapy at any given time, the treatment-active population across these regions.
Signs and symptoms of Multiple Sclerosis
A 2025 US patient registry reported a median diagnostic delay of two months, though the mean reached 22.8 months, and 40.4% of patients recalled an earlier misdiagnosis before MS was confirmed.
Optic neuritis

Optic neuritis

Unilateral visual blurring with pain on eye movement, present in around 25% of initial presentations.

Lhermitte's sign

Lhermitte's sign

An electric shock sensation down the spine on neck flexion, highly characteristic of MS.

Fatigue

Fatigue

The most prevalent symptom throughout the disease course, reported by more than 80% of patients.

Cognitive impairment

Cognitive impairment

Slowed processing speed, attention and working memory, often described by patients as MS fog.

Progression independent of relapse activity

Progression independent of relapse activity

Gradual worsening of gait, dexterity and cognition without new relapses or MRI lesions.

Key challenges from product development to launch

Strategy and Business

Strategy and Business

  • The wrong disease or indication selected for investment
  • Indications tackled in the wrong order due to shaky success estimates
  • R&D returns slipping below the cost of capital
Clinical Development

Clinical Development

  • Trials delayed by low patient recruitment
  • High screen-failure rates that raise trial cost
  • Mixed cohorts that make the signals difficult to detect
HEOR, Access & Value

HEOR, Access & Value

  • A value case that arrives too late or is underdeveloped
  • Eligible population under-counted, budget-impact case unsubstantiated
  • Approved by the regulator, delayed at HTA
Medical Affairs

Medical Affairs

  • Fragmented, differently-coded healthcare data
  • Diagnostic delay that is long and unequal
  • No shared evidence base across functions
Launch and Commercial

Launch and Commercial

  • Launch planned without a view of the number of findable patients
  • Targeting too broad a population slows early uptake
  • RWE started too late to build the case

How Volv Global Helps

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.

Case Studies about Neurology diseases

Insights